Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 13 Show results per page	View Search Criteria \| Help With Results

Last Modified: 1/23/2007 First Published: 11/24/2002


1.		Phase III Randomized Study of Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				MRC-BR12 EU-20114, ISRCTN83176944, NCT00052455

Last Modified: 6/13/2008 First Published: 5/28/2004


2.		Phase III Randomized Adjuvant Study of Standard-Dose Versus Reduced-Dose Craniospinal Radiotherapy and Posterior Fossa Boost Versus Tumor Bed Boost Radiotherapy in Combination With Chemotherapy Comprising Vincristine, Cisplatin, Lomustine, and Cyclophosphamide in Pediatric Patients With Newly Diagnosed Standard-Risk Medulloblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				3 to 21 at diagnosis				NCI				COG-ACNS0331 ACNS0331, NCT00085735

Last Modified: 12/20/2006 First Published: 1/13/2006


3.		Phase III Randomized Study of Standard Chemoradiotherapy With Versus Without High-Dose Methotrexate in Pediatric Patients With Newly Diagnosed, Malignant High-Grade Glioma or Diffuse Intrinsic Pontine Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				3 to 18				Other				GPOH-HIT-GBM-D EU-205100, NCT00278278


4.		Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				60 and over				Other				CHUBX 2007/13 NCT00590837


5.		Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2004-0595 NCT00527657

Last Modified: 11/7/2006 First Published: 3/1/2002


6.		Phase II Study of Adjuvant Reduced-Dose Craniospinal Radiotherapy With Vincristine Followed By Maintenance Chemotherapy in Children With Newly Diagnosed Standard-Risk Posterior Fossa Primitive Neuroectodermal Tumor or Medulloblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				3 to 30 at initial diagnosis				Other				CHP-693 CHP-IRB-2001-12-2301, NCI-V01-1680, NCT00031590

Last Modified: 10/5/2007 First Published: 3/24/2003


7.		Phase II Pilot Study of Post-Operative Intrathecal Radioimmunotherapy, Reduced-Dose Craniospinal Radiotherapy With Intensity-Modulated Radiotherapy Boost, and Chemotherapy in Patients With Standard-Risk Medulloblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				3 and over				NCI				MSKCC-02088 NCT00058370

Last Modified: 12/11/2006 First Published: 12/22/2005


8.		Phase II Study of Hyperfractionated Accelerated Radiotherapy (HART) Followed By Adjuvant Combination Chemotherapy Comprising Lomustine, Cisplatin, and Vincristine in Pediatric Patients With Nonpineal Supratentorial Primitive Neuroectodermal Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				3 to 18				Other				CCLG-CNS-2004-01 EU-20580, NCT00274911

Last Modified: 5/23/2007 First Published: 1/6/2006


9.		Phase II Study of Adjuvant Hyperfractionated Accelerated Radiotherapy (HART) Followed By Maintenance Chemotherapy Comprising Lomustine, Cisplatin, and Vincristine in Young Patients With Metastatic Medulloblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				3 to 21				Other				CCLG-CNS-2001-06 EU-20577, NCT00276666


10.		Second-Line Treatment in Patients With Small Cell Lung Cancer (SCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				GFPC 05-01 NCT00418743

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute